Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

…, L Chen, CH Yun, D Li, M Capelletti, AB Cortot… - Nature, 2009 - nature.com
The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant
non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance …

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 …

…, S Orlov, D Cortinovis, CJ Yu, M Hochmair, AB Cortot… - The Lancet, 2017 - thelancet.com
Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged
non-small-cell lung cancer (NSCLC) is not known. We assessed the …

[PDF][PDF] Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives

J Mazières, S Peters, B Lepage, AB Cortot… - Journal of clinical …, 2013 - cancer.net
… (B) Human epidermal growth factor receptor 2 (HER2) immunohistochemistry with score 2
(antibody 4B5). (C) Fluorescent in situ hybridization with HER2 amplification (HER2 in red; …

[HTML][HTML] Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

…, E Felip, R Veillon, H Sakai, AB Cortot… - … England Journal of …, 2020 - Mass Medical Soc
Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). …

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

AB Cortot, CE Repellin, T Shimamura, M Capelletti… - Cancer research, 2013 - AACR
The clinical efficacy of EGF receptor (EGFR) kinase inhibitors gefitinib and erlotinib is limited
by the development of drug resistance. The most common mechanism of drug resistance is …

Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas

AB Cortot, PA Jänne - European Respiratory Review, 2014 - Eur Respiratory Soc
The discovery of epidermal growth factor receptor (EGFR) mutations in nonsmall cell lung
cancer (NSCLC) has allowed the identification of a subset of patients whose tumours are …

Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non–small-cell lung cancer harboring HER2 mutations: Results from the IFCT …

…, D Moro-Sibilot, F Pinquie, AB Cortot… - Journal of Clinical …, 2022 - ingentaconnect.com
PURPOSE HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-2%
of patients with non–small-cell lung cancer (NSCLC). No targeted therapy is approved …

EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti‐EGFR treatment of a rare lung malignancy

A Italiano, AB Cortot, M Ilie… - … journal of cancer, 2009 - Wiley Online Library
Sarcomatoid carcinomas (SC) of the lung are uncommon malignant tumors composed of
carcinomatous and sarcomatous cell components and characterized by a more aggressive …

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical …

…, R Veillon, MC Garassino, J Raskin, AB Cortot… - Clinical Cancer …, 2022 - AACR
Purpose: Primary analysis of VISION showed tepotinib had durable clinical activity in patients
with MET exon 14 (METex14) skipping non–small cell lung cancer (NSCLC). We present …

Exon 14 deleted MET receptor as a new biomarker and target in cancers

AB Cortot, Z Kherrouche… - Journal of the …, 2017 - academic.oup.com
Inhibitors of the receptor tyrosine kinase (RTK) MET have been ineffective at treating cancer,
possibly because of lack of knowledge that would allow selection of tumors likely to …